The Cocktail Report (sound really smart around your friends):
On October 1, 2026, FDA Chief Scientist Steven Kozlowski said aging and longevity will be a topic in the agency's next Focus Areas of Regulatory Science report.
That report lists the science the FDA considers most important across all its centers, and the 2022 edition never used the terms "aging research" or "longevity medicine."
An FDA drug-evaluation director laid out two routes to proof: help several age-related diseases at once, or slow decline across many body and brain functions.
A senior FDA reviewer expects the first approvable aging trials to target older, higher-risk people and hard outcomes such as death or new chronic disease.
He named his own office as the home for aging as a drug indication.
Every drug in your medicine cabinet was approved to treat a specific disease. None was approved to slow aging itself.
On October 1, 2026, the agency's top scientist said that is starting to change. Speaking at ARDD 2026, the Aging Research and Drug Discovery Meeting held at Harvard, Steven Kozlowski said aging and longevity will be included in the FDA's updated Focus Areas of Regulatory Science, or FARS.
What FARS is
FARS is a high-level report on the research the FDA treats as most important across its centers and labs. Regulatory science means building the tools and standards the agency uses to judge whether a product is safe and works.
The 2022 edition did not include the terms "aging research" or "longevity medicine". Kozlowski said the new edition would come out early in fiscal year 2027, which began October 1, without naming a month.
Two routes to proving a drug slows aging
Jeffrey Siegel, who directs the FDA's Office of Drug Evaluation Sciences, described two possible approaches. The first is to show one drug helps a second and third age-related disease, until the shared mechanism looks like the real target.
The second is to pick people already declining in areas like thinking, frailty, hearing and vision. A trial would then show that treated people decline more slowly than an untreated group.
Who gets tested first?
Justin Penzenstadler, an acting associate director in the FDA office covering heart, blood, hormone and kidney drugs, thinks the first trials that could win approval will measure prevention of age-related diseases or death. His reasoning was about risk and reward: "We're thinking about potentially treating somebody for thirty years to derive a couple-year benefit".
That math is why he favors starting with older, higher-risk people. If you are in your 70s with a few chronic conditions, you fit the profile of the first volunteers these trials will want.
The biomarker problem
If you have paid for a biological age test, here is how the FDA sees that number. A marker like that does not count as proof a drug works until a long chain of studies ties its changes to real health outcomes.
Siegel drew the line between a prognostic biomarker, which predicts future risk, and a surrogate endpoint, which also changes with treatment in a way that reflects real benefit. Penzenstadler's top request was a shared industry group that agrees on "a cookbook of biomarkers" so trials can pool results.
The officials also warned about a catch. Drugs such as GLP-1 agonists already cut heart attacks and strokes, so a longevity trial using them could show longer life for reasons already known.
What this means for you
Nothing changes at your pharmacy this year. What changes is that drug makers now know the office to call and the kind of evidence the FDA wants, delivered through a standard Investigational New Drug application.
What this does and does not mean
To be frank, FARS is a research agenda, not an approval rule, and no official offered a formal aging indication. The new report's wording and release date are not public yet.
This account comes from three independent news reports of the panel, read in full, because no official transcript or video was available. Harvard Medical School dean George Daley opened the same meeting by warning that some claims in the field "far exceed what one can responsibly conclude from our current understanding of the biology.
Why Should You Care?
For the first time, the FDA's chief scientist has said out loud that aging belongs on the agency's scientific agenda. That does not put an anti-aging pill on the shelf, but it gives companies a clearer target to aim for.
1. Philippidis A. "FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates." GEN, Genetic Engineering & Biotechnology News. October 2, 2026. https://www.genengnews.com/topics/translational-medicine/fda-to-highlight-aging-longevity-medicine-in-planned-fars-update/
2. Mazin A. "FDA Leaders Name Longevity a Priority at ARDD." Lifespan.io. October 2, 2026. https://lifespan.io/fda-leaders-name-longevity-a-priority-at-ardd/
3. Newman, P. "FDA puts aging on its regulatory science agenda." Longevity.Technology. October 1, 2026. https://longevity.technology/news/fda-puts-aging-on-its-regulatory-science-agenda/
